These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26424421)

  • 1. De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder.
    Přibylová L; Kolek M; Veselá Š; Duba J; Šlesinger J; Dolečková J
    J Psychiatr Res; 2015 Nov; 70():33-7. PubMed ID: 26424421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
    Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
    Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
    Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
    Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
    J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong.
    Choon JWY; Wu DBC; Chong HY; Lo WTL; Chong CSY; Chung WS; Chui EMC; Tomlinson B; Lee VWY; Lee SC; Lee KKC
    J Med Econ; 2019 Mar; 22(3):273-279. PubMed ID: 30561238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
    Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
    Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
    Williams W; McKinney C; Martinez L; Benson C
    J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection.
    Mesones-Peral JE; Gurillo-Muñoz P; Sánchez-Sicilia MP; Miller A; Griñant-Fernández A
    Rev Psiquiatr Salud Ment; 2017; 10(1):33-37. PubMed ID: 27053545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
    Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
    J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
    Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment.
    Jiang Y; Ni W
    J Manag Care Spec Pharm; 2015 Sep; 21(9):780-92. PubMed ID: 26308225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative evaluation of clinical and economic efficiency of paliperidone in various dosage forms used in patients with schizophrenia].
    D'yakov IN; Zyryanov SK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):85-92. PubMed ID: 28374699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
    Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
    J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
    Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
    Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early treatment response predicted subsequent clinical response in patients with schizophrenia taking paliperidone extended-release.
    Yeh EC; Huang MC; Tsai CJ; Chen CT; Chen KY; Chiu CC
    Psychiatry Res; 2015 Nov; 230(1):13-8. PubMed ID: 26319696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
    Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
    Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.